Amyloid-targeting drug for Parkinson's with Alzheimer's changes
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a drug called lecanemab, which targets amyloid plaques in the brain, in people who have both Parkinson's disease and signs of Alzheimer's disease. It aims to see if the drug can help with thinking and memory problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Parkinson's disease.
- A brain PET scan must show amyloid plaques (a sign of Alzheimer's disease).
- You should have mild cognitive impairment (minor memory or thinking problems) or early dementia.
- You must be between 50 and 90 years old.
- You must not have other brain conditions that could explain your symptoms, and lecanemab must be safe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This trial tests whether a monoclonal antibody drug can help people with early Alzheimer's disease or mild cognitive impairment. The drug targets amyloid plaques in the brain, which are detected using a special PET scan before treatment.
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.